Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY)
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $7.00 price objective on the stock, down from their previous price objective of $12.00. Several other analysts have also issued reports on the […]
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $7.00 price objective on the stock, down from their previous price objective of $12.00. Several other analysts have also issued reports on the […]
